We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
  1. You have to credit our authors.
  2. You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
  5. The easiest way to get the article on your site is to embed the code below.
For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

Pakistan's ministry of health has ordered new clinical trials on a locally made hepatitis B drug that ran into controversy over corruption charges and trial irregularities.
The local drug for hepatitis B, which affects seven million persons in the country, was developed at the Lahore-based Centre of Advanced Molecular Biology (CAMB).
But, controversy has dogged the drug trials and launch. Pakistan's science ministry has charged CAMB with funds misuse during drug development, and referred its audit findings on CAMB to the country’s Federal Investigation Agency.   
The health ministry says CAMB conducted studies on humans without permission, and used a small sample size.
Last month (10 January), the health ministry told the CAMB to conduct fresh clinical trials and initiate steps to produce 100,000 vials of the drug.